Printer Friendly

ANGEION REPORTS FIRST QUARTER SALES UP 13 PERCENT

 ANGEION REPORTS FIRST QUARTER SALES UP 13 PERCENT
 MINNEAPOLIS, Dec. 12 /PRNewswire/ -- Angeion Corporation


(NASDAQ: ANGN) reported sales of $1,420,591 for the first quarter ended Oct. 31, 1991. This represents a 13 percent increase over sales of $1,252,196 for the first quarter ended Oct. 31, 1990.
 Increased expenses relating to Angeion's research and development for its three operating units resulted in a loss of $1,055,820, or $0.11 per share, for the first quarter ended Oct. 31, 1991. This compares to a loss of $203,583, or $0.02 per share, for the first quarter ended Oct. 31, 1990.
 "Overall, we had a good quarter despite the loss of one of our large customers last fiscal year," said Wendall L. King, chairman and CEO. "This is the first quarter we would have seen any significant impact of that loss. While OEM sales for the quarter decreased when compared to the same period last year, proprietary products sales increased from 32 percent to 53 percent of total sales during the same quarter last year resulting in an overall increase in sales for the quarter ended Oct. 31, 1991. We are moving in the right direction, building proprietary product sales as we continue to pursue additional OEM sales. We're also very pleased with the progress of our two clinical programs on the laser catheter device."
 During the first quarter, Angeion:
 -- Began a second separate clinical program for the laser catheter device using it in open chest surgeries to cure ventricular tachycardia (rapid irregular heartbeats).
 -- Signed its first U.S. Government contract and began shipping angiography and angioplasty accessory products to U.S. military installations. The total U.S. Government facilities market is estimated at approximately $20 million.
 -- Received additional market approval from the Government of Japan to market two additional lines of accessory devices in Japan. This total angioplasty and angiography accessories market is estimated to be between $160 and $200 million.
 -- Raised approximately $1.9 million in net proceeds in a September financing effort. (On Dec. 11, the company announced it had raised an additional $2.1 million, which will result in approximately $1.9 million in net proceeds.)
 Minneapolis-based Angeion Corporation is a manufacturer of cardiovascular products. Angeion's subsidiaries, AngeLase, Inc. and AngeMed, Inc., are developing products for treating arrhythmias and electrophysiology products. Angeion is also traded on the Boston Stock Exchange under the symbol ANI.
 ANGEION CORPORATION
 CONDENSED STATEMENTS OF OPERATIONS
 (Unaudited)
 First Quarter Ended
 10/31/91 10/31/90
 Net sales $1,420,591 $1,252,196
 Net loss (1,055,820) (203,583)
 Loss per common share $(0.11) $(0.02)
 Weighted average number of
 shares outstanding 9,201,381 8,175,860
 CONDENSED BALANCE SHEETS
 (Unaudited)
 10/31/91 7/31/91
 Current assets $4,111,739 $3,089,862
 Property and other 2,489,056 2,255,775
 Total assets 6,600,795 5,345,637
 Current liabilities 1,032,885 683,552
 Long-term debt 129,017 117,604
 Shareholders' equity 5,438,893 4,544,481
 Total liabilities and equity $6,600,795 $5,345,637
 -0- 12/12/91
 /CONTACT: Brenda Roth of Angeion, 612-550-9388/
 (ANGN) CO: Angeion Corporation ST: Minnesota IN: MTC SU: ERN


KH -- MN007 -- 2028 12/12/91 14:46 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 12, 1991
Words:548
Previous Article:LEBOVISION RELEASES 'AMERICA'S LOWEST VISA AND MASTERCARD INTEREST RATES'
Next Article:OFFICE OF THE COMPTROLLER OF THE CURRENCY ANNOUNCES ENFORCEMENT ACTIONS TAKEN AGAINST BANKERS, NATIONAL BANKS
Topics:


Related Articles
ANGEION REPORTS THIRD QUARTER FIGURES
ANGEION RELEASES SECOND QUARTER FIGURES
ANGEION REPORTS THIRD QUARTER FIGURES
ANGEION REPORTS FIRST QUARTER RESULTS
ANGEION REPORTS SECOND QUARTER RESULTS
ANGEION REPORTS THIRD QUARTER RESULTS; SECURES INITIAL BRIDGE LOAN
ANGEION REPORTS FIRST QUARTER RESULTS
Angeion Reports First Quarter Sales Up More Than 10 Times Previous Year
Angeion Reports Second Quarter Results; Sales Increase 13 Percent
Angeion Reports 33 Percent Growth in ICD Sales in Third Quarter.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters